vs
Side-by-side financial comparison of iRhythm Holdings, Inc. (IRTC) and VICOR CORP (VICR). Click either name above to swap in a different company.
iRhythm Holdings, Inc. is the larger business by last-quarter revenue ($208.9M vs $113.0M, roughly 1.8× VICOR CORP). VICOR CORP runs the higher net margin — 18.3% vs 2.7%, a 15.6% gap on every dollar of revenue. On growth, iRhythm Holdings, Inc. posted the faster year-over-year revenue change (27.1% vs 20.2%). Over the past eight quarters, iRhythm Holdings, Inc.'s revenue compounded faster (25.8% CAGR vs 14.7%).
iRhythm Holdings is a digital healthcare company focused on cardiac care, developing and commercializing wearable ambulatory heart monitoring devices paired with AI-powered analytical tools. It primarily serves healthcare providers and patients across the United States, helping to detect undiagnosed arrhythmias such as atrial fibrillation through convenient long-term heart rhythm tracking that delivers actionable clinical insights.
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
IRTC vs VICR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $208.9M | $113.0M |
| Net Profit | $5.6M | $20.7M |
| Gross Margin | 70.9% | — |
| Operating Margin | 1.1% | 59.7% |
| Net Margin | 2.7% | 18.3% |
| Revenue YoY | 27.1% | 20.2% |
| Net Profit YoY | 518.5% | 713.9% |
| EPS (diluted) | $0.18 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.0M | ||
| Q4 25 | $208.9M | $107.3M | ||
| Q3 25 | $192.9M | $110.4M | ||
| Q2 25 | $186.7M | $96.0M | ||
| Q1 25 | $158.7M | $94.0M | ||
| Q4 24 | $164.3M | $96.2M | ||
| Q3 24 | $147.5M | $93.2M | ||
| Q2 24 | $148.0M | $85.9M |
| Q1 26 | — | $20.7M | ||
| Q4 25 | $5.6M | $46.5M | ||
| Q3 25 | $-5.2M | $28.3M | ||
| Q2 25 | $-14.2M | $41.2M | ||
| Q1 25 | $-30.7M | $2.5M | ||
| Q4 24 | $-1.3M | $10.2M | ||
| Q3 24 | $-46.2M | $11.6M | ||
| Q2 24 | $-20.1M | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | 70.9% | 55.4% | ||
| Q3 25 | 71.1% | 57.5% | ||
| Q2 25 | 71.2% | 95.9% | ||
| Q1 25 | 68.8% | 47.2% | ||
| Q4 24 | 70.0% | 52.4% | ||
| Q3 24 | 68.8% | 49.1% | ||
| Q2 24 | 69.9% | 49.8% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | 1.1% | 14.6% | ||
| Q3 25 | -4.4% | 18.9% | ||
| Q2 25 | -10.0% | 47.3% | ||
| Q1 25 | -20.5% | -0.2% | ||
| Q4 24 | -2.5% | 9.6% | ||
| Q3 24 | -34.1% | 5.8% | ||
| Q2 24 | -15.5% | 0.2% |
| Q1 26 | — | 18.3% | ||
| Q4 25 | 2.7% | 43.4% | ||
| Q3 25 | -2.7% | 25.6% | ||
| Q2 25 | -7.6% | 42.9% | ||
| Q1 25 | -19.3% | 2.7% | ||
| Q4 24 | -0.8% | 10.7% | ||
| Q3 24 | -31.3% | 12.4% | ||
| Q2 24 | -13.6% | -1.4% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | $0.18 | $1.01 | ||
| Q3 25 | $-0.16 | $0.63 | ||
| Q2 25 | $-0.44 | $0.91 | ||
| Q1 25 | $-0.97 | $0.06 | ||
| Q4 24 | $-0.03 | $0.24 | ||
| Q3 24 | $-1.48 | $0.26 | ||
| Q2 24 | $-0.65 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $583.8M | $404.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $152.7M | $754.1M |
| Total Assets | $1.0B | $804.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $404.2M | ||
| Q4 25 | $583.8M | $402.8M | ||
| Q3 25 | $565.2M | $362.4M | ||
| Q2 25 | $545.5M | $338.5M | ||
| Q1 25 | $520.6M | $296.1M | ||
| Q4 24 | $535.6M | $277.3M | ||
| Q3 24 | $522.0M | $267.6M | ||
| Q2 24 | $561.5M | $251.9M |
| Q1 26 | — | $754.1M | ||
| Q4 25 | $152.7M | $711.6M | ||
| Q3 25 | $121.9M | $630.1M | ||
| Q2 25 | $103.7M | $608.6M | ||
| Q1 25 | $86.7M | $580.3M | ||
| Q4 24 | $90.9M | $570.1M | ||
| Q3 24 | $71.8M | $554.6M | ||
| Q2 24 | $99.2M | $537.2M |
| Q1 26 | — | $804.9M | ||
| Q4 25 | $1.0B | $785.8M | ||
| Q3 25 | $995.2M | $710.2M | ||
| Q2 25 | $964.0M | $693.5M | ||
| Q1 25 | $926.1M | $665.0M | ||
| Q4 24 | $931.4M | $641.1M | ||
| Q3 24 | $909.7M | $632.8M | ||
| Q2 24 | $919.2M | $613.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.2M | — |
| Free Cash FlowOCF − Capex | $14.5M | — |
| FCF MarginFCF / Revenue | 6.9% | — |
| Capex IntensityCapex / Revenue | 5.6% | — |
| Cash ConversionOCF / Net Profit | 4.70× | — |
| TTM Free Cash FlowTrailing 4 quarters | $34.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $26.2M | $15.7M | ||
| Q3 25 | $34.9M | $38.5M | ||
| Q2 25 | $27.7M | $65.2M | ||
| Q1 25 | $-7.9M | $20.1M | ||
| Q4 24 | $19.2M | $10.1M | ||
| Q3 24 | $24.3M | $22.6M | ||
| Q2 24 | $11.8M | $15.6M |
| Q1 26 | — | — | ||
| Q4 25 | $14.5M | $10.2M | ||
| Q3 25 | $20.1M | $34.5M | ||
| Q2 25 | $17.3M | $59.0M | ||
| Q1 25 | $-17.3M | $15.6M | ||
| Q4 24 | $12.4M | $8.4M | ||
| Q3 24 | $15.5M | $14.1M | ||
| Q2 24 | $3.4M | $9.4M |
| Q1 26 | — | — | ||
| Q4 25 | 6.9% | 9.5% | ||
| Q3 25 | 10.4% | 31.2% | ||
| Q2 25 | 9.3% | 61.5% | ||
| Q1 25 | -10.9% | 16.6% | ||
| Q4 24 | 7.5% | 8.7% | ||
| Q3 24 | 10.5% | 15.2% | ||
| Q2 24 | 2.3% | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | 5.6% | 5.2% | ||
| Q3 25 | 7.7% | 3.6% | ||
| Q2 25 | 5.6% | 6.5% | ||
| Q1 25 | 5.9% | 4.8% | ||
| Q4 24 | 4.2% | 1.8% | ||
| Q3 24 | 6.0% | 9.1% | ||
| Q2 24 | 5.7% | 7.2% |
| Q1 26 | — | — | ||
| Q4 25 | 4.70× | 0.34× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.58× | ||
| Q1 25 | — | 7.93× | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | — | 1.95× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRTC
| Commercial Payors | $111.7M | 53% |
| Centers For Medicare And Medicaid | $49.2M | 24% |
| Healthcare Institutions | $34.3M | 16% |
| Non Contracted Third Party Payors | $13.7M | 7% |
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
